Kite Pharma Reports Positive Data From ZUMA-1, Evaluating a CAR-T Treatment
Median overall survival was not yet reached at a median follow-up of 8.7 months on the company’s ZUMA-1 trial.
Kite Pharma, a pioneer in developing the chimeric antigen receptor (CAR)-T cell treatment,
The trial, being conducted in patients with chemotherapy-resistant aggressive B-cell non-Hodgkin lymphoma (NHL), is testing axicabtagene ciloleucel (previously referred to as KTE-C19). Interim analysis of the data showed that the trial met its primary endpoints of objective response rate (ORR), complete response (CR), and partial response (PR), following a single infusion of axicabtagene ciloleucel.
Of the 101 trial participants, 41% achieved ORR at 6 months (P <.0001), 36% had a CR, and 5% of patients had a durable PR. One of the partial responders became a complete responder at 9 months following infusion. More importantly, the trial was yet to reach a median OS at nearly 9 months of follow-up.
The following grade 3 or higher adverse events were reported from the trial:
- Anemia (43%)
- Neutropenia (39%)
- Decreased neutrophil count (32%)
- Febrile neutropenia (31%)
- Decreased white blood cell count (29%)
- Thrombocytopenia (24%)
- Encephalopathy (21%)
- Decreased lymphocyte count (20%)
No cases of cerebral edema were reported, unlike the
“Several patients we treated at Moffitt Cancer Center experienced a rapid and durable complete response with this first-of-its kind therapy,” Frederick L. Locke, MD, ZUMA-1 co-lead investigator, and director of research for the Immune Cell Therapy Program at Moffitt Cancer Center, said in a
The company is planning to submit a rolling Biologics License Application based on these results by the end of the first quarter of 2017.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
September 17th 2025
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025